Sedatives and Hypnotics

Classification

Benzodiazepines: long(diazepam, chlordiazepoxide, clonazepam) · short/intermediate(lorazepam, alprazolam, oxazepam) · ultra-short(midazolam, triazolam). Z-drugs: zolpidem, zopiclone, zaleplon. Barbiturates: phenobarbitone(long, now mainly antiepileptic), thiopentone(ultra-short, anaesthetic) — largely obsolete as sedative-hypnotics. Melatonin agonist: ramelteon. Orexin antagonist: suvorexant.

Mechanism

Benzodiazepines: bind α/γ subunit interface of GABA-A(distinct from GABA site AND barbiturate site) → POSITIVE ALLOSTERIC MODULATOR → ↑FREQUENCY of Cl- channel opening, requires GABA present(no effect alone). → SAFETY CEILING(capped by endogenous GABA) → pure OD rarely fatal alone(dangerous only combined with other depressants — opioids/alcohol, additive/synergistic).

Barbiturates: different site, ↑DURATION of opening + at HIGH conc, opens channel DIRECTLY, GABA-INDEPENDENT → NO ceiling → OD far more dangerous(fatal resp/cardiac depression via unbounded direct activation).

Z-drugs: same benzodiazepine site, chemically unrelated, SELECTIVE for α1 subunit(sedative/hypnotic) over α2/α3(anxiolytic/muscle-relaxant) → hypnosis with LESS next-day sedation/anxiolysis/muscle relaxation than non-selective benzodiazepine → developed specifically as hypnotics.

Ramelteon: MT1/MT2 melatonin receptor agonist(suprachiasmatic nucleus) — reinforces endogenous sleep-wake signal, NOT global CNS depression. Suvorexant: orexin(hypocretin, wake-promoting) receptor ANTAGONIST — removes wake-drive rather than adding sedation. Both: minimal abuse/dependence potential vs GABAergic hypnotics(no GABA-potentiating reward).

Adverse Effects

Benzodiazepines: sedation/drowsiness/↓psychomotor performance(driving hazard, worse with long-acting/accumulation) · anterograde amnesia(exploited: midazolam pre-endoscopy; liability in routine use) · tolerance+dependence+WITHDRAWAL(rebound anxiety/insomnia/seizures — SAME GABA-downregulation logic as alcohol withdrawal → TAPER, don’t abruptly stop) · resp depression(worse +other depressants or ↓resp reserve e.g. severe COPD) · paradoxical excitement/disinhibition(children, elderly).

Barbiturates: SAME liabilities as benzos but MORE SEVERE + potent hepatic CYP450 induction(↓efficacy of many co-drugs — relevant to phenobarbitone’s antiepileptic interactions) + narrow TI, NO CEILING → far more dangerous OD → mostly displaced by benzodiazepines except phenobarbitone(antiepileptic)/thiopentone(anaesthesia).

Z-drugs: milder than benzos overall(receptor selectivity) BUT complex sleep-related behaviours(sleep-walking/driving/eating, no memory) = specific drug-class-labelled risk, esp. zolpidem.

Antidote

Flumazenil: competitive benzodiazepine-site antagonist(same site, no intrinsic activity) — reverses benzo sedation/resp depression. CAUTION: chronic benzo use or co-ingested pro-convulsant(e.g. TCA) → abrupt GABA-potentiation removal can precipitate WITHDRAWAL SEIZURES or unmask TCA seizure toxicity the benzo was masking — NOT a routine no-hesitation reversal agent.

Clinical Relevance

GABA-INDEPENDENT(barbiturate) vs GABA-DEPENDENT(benzodiazepine) = the single fact explaining almost everything else: why benzos replaced barbiturates(safety ceiling), why barbiturate OD = genuine emergency while pure benzo OD usually isn’t, why flumazenil(benzo-site-specific) does NOTHING for barbiturate OD — reversing occupancy at a shared allosteric site can’t reverse a different class’s GABA-independent direct channel activation.

Classification

Benzodiazepines
- Long-acting: diazepam, chlordiazepoxide, clonazepam
- Short/intermediate-acting: lorazepam, alprazolam, oxazepam
- Ultra-short-acting: midazolam, triazolam
Non-benzodiazepine “Z-drugs”: zolpidem, zopiclone, zaleplon
Barbiturates: phenobarbitone (long-acting, now mainly an antiepileptic), thiopentone (ultra-short, an anaesthetic — covered under General Anaesthetics), largely obsolete as sedative-hypnotics
Melatonin receptor agonist: ramelteon
Orexin receptor antagonist: suvorexant

Mechanism of Action

Benzodiazepines bind a specific site at the interface of the α and γ subunits of the GABA-A receptor (distinct from the GABA-binding site itself and from the barbiturate site) and act as positive allosteric modulators — they do not open the chloride channel on their own, but increase the frequency of channel opening in the presence of GABA, requiring GABA to be present to have any effect at all. This is the single most important mechanistic distinction from barbiturates (below) and explains benzodiazepines’ comparatively wide safety margin: since their effect is capped by endogenous GABA availability, there is a ceiling to how much they can depress the CNS, which is why pure benzodiazepine overdose is rarely fatal on its own (though dangerous in combination with other CNS depressants, particularly opioids or alcohol, where the combined depression is additive/synergistic beyond what either produces alone).

Barbiturates also potentiate GABA-A receptor activity, but at a different binding site, and by a different mechanism: they increase the duration of channel opening, and — critically — at higher concentrations can open the chloride channel directly, independent of GABA — this GABA-independence is exactly why barbiturates lack benzodiazepines’ safety ceiling and why barbiturate overdose is far more dangerous, capable of producing fatal respiratory and cardiovascular depression through direct, unbounded channel activation.

Z-drugs (zolpidem, zopiclone, zaleplon) bind the same benzodiazepine site on the GABA-A receptor but are chemically unrelated to benzodiazepines, and show relative selectivity for GABA-A receptors containing the α1 subunit (associated predominantly with sedative/hypnotic effect) over α2/α3-subunit-containing receptors (associated more with anxiolytic and muscle-relaxant effects) — this selectivity is the pharmacological basis for Z-drugs producing hypnosis with comparatively less next-day sedation, anxiolysis, and muscle relaxation than a non-selective benzodiazepine, and is why they were developed specifically as hypnotics rather than general-purpose anxiolytics.

Melatonin receptor agonists (ramelteon) and orexin receptor antagonists (suvorexant) work through entirely separate, non-GABAergic mechanisms — ramelteon activates MT1/MT2 melatonin receptors in the suprachiasmatic nucleus, reinforcing the endogenous sleep-wake signal rather than globally depressing the CNS; suvorexant blocks orexin (hypocretin) receptors, orexin being a wake-promoting neuropeptide, so blocking it removes wake-drive rather than adding sedation. Both carry minimal abuse/dependence potential compared with GABAergic hypnotics, precisely because they don’t produce the same rewarding, GABA-potentiating CNS depression.

Adverse Effects

Benzodiazepines: sedation, drowsiness, impaired psychomotor performance (a genuine driving/machinery-operation hazard, more pronounced with longer-acting agents given accumulation and residual next-day effect) · anterograde amnesia (a property deliberately exploited for procedural sedation, e.g. midazolam before endoscopy, but a liability in routine hypnotic use) · tolerance and dependence with chronic use, and a genuine, sometimes severe withdrawal syndrome (rebound anxiety, insomnia, and — in severe cases — seizures, mechanistically the same GABA-downregulation/compensatory-adaptation logic as alcohol withdrawal, hence the recommendation to taper rather than abruptly stop long-term benzodiazepine therapy) · respiratory depression (more significant in combination with other CNS depressants or in patients with compromised respiratory reserve, e.g. severe COPD) · paradoxical excitement/disinhibition, more common in children and the elderly.

Barbiturates: the same sedation/dependence/withdrawal liabilities as benzodiazepines but more severe across the board, plus potent hepatic enzyme induction (CYP450, reducing the efficacy of numerous co-administered drugs — a specific, examined interaction mechanism relevant to phenobarbitone’s continued antiepileptic use) and a genuinely narrow therapeutic index with no ceiling effect, making overdose (accidental or intentional) far more dangerous than benzodiazepine overdose — the central reason barbiturates have been almost entirely displaced by benzodiazepines for sedation/anxiolysis, retaining a role today mainly as antiepileptics (phenobarbitone) and induction anaesthetics (thiopentone) rather than as routine hypnotics.

Z-drugs: broadly similar but milder adverse-effect profile than benzodiazepines (per the receptor-selectivity above), though complex sleep-related behaviours (sleep-walking, sleep-driving, sleep-eating with no memory of the episode) are a specific, drug-class-labelled risk, particularly with zolpidem.

Antidote and Reversal

Flumazenil: a competitive benzodiazepine receptor antagonist (binds the same site, no intrinsic activity of its own) — reverses benzodiazepine sedation/respiratory depression, used for benzodiazepine overdose or to reverse procedural sedation. Must be used cautiously in a patient on chronic benzodiazepine therapy or with co-ingested pro-convulsant drugs (e.g. tricyclic antidepressants) — abruptly removing the benzodiazepine’s GABA-potentiating effect can precipitate withdrawal seizures or unmask a tricyclic’s own seizure-inducing toxicity that the benzodiazepine had been masking, a genuinely important, frequently examined caution rather than a routine reversal agent to give without hesitation.

Clinical Relevance

The GABA-independent-versus-GABA-dependent distinction between barbiturates and benzodiazepines is the single fact from which nearly every other comparison in this topic follows: why benzodiazepines have largely replaced barbiturates for sedation (safety ceiling), why barbiturate overdose is a genuine emergency while pure benzodiazepine overdose usually is not, and why flumazenil (a benzodiazepine-site-specific antagonist) does nothing for barbiturate overdose — a drug that reverses one class’s effect by removing occupancy at a shared allosteric site cannot reverse a different class’s ability to open the channel independent of that site altogether.

GABA-A receptor with benzodiazepine, barbiturate, and GABA binding sites marked separately, showing frequency-of-opening (benzodiazepine) vs duration-of-opening plus GABA-independent direct activation (barbiturate).
Z-drug receptor subunit selectivity (α1 vs α2/α3) mapped to hypnotic vs anxiolytic/muscle-relaxant effect.